Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bayard L Powell

Showing results (11-20 of 164) with videos related to

Pageof 17
Sort By:
Future Oncology (London, England)|September 13, 2019
Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III studyTimothy S Pardee, Sanjeev Luther, Marc Buyse, et al.
British Journal of Haematology|February 19, 2002
Allogenic marrow grafts from unrelated donors with congenital pericentric inversion of chromosome 9Yi-Kong Keung, Mark Pettenati, David D Hurd, et al.
Cancer Genetics and Cytogenetics|July 30, 2003
Constitutional pericentric inversion of chromosome 9 and acute leukemiaYi-Kong Keung, Mary Ann Knovich, Bayard L Powell, et al.
Leukemia Research|May 4, 2004
Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literatureYi-Kong Keung, Michael Beaty, Bayard L Powell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemiaArthur E Frankel, Bayard L Powell, Philip D Hall, et al.
Current Protein & Peptide Science|October 9, 2002
Anthrax fusion protein therapy of cancerArthur E Frankel, Bayard L Powell, Nick S Duesbery, et al.
Journal of Cancer Research and Clinical Oncology|March 6, 2003
19-nor-1alpha,25-dihydroxyvitamin D(2) (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell linesIstván Molnár, Timothy Kute, Mark C Willingham, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 1, 2010
Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapyMartin Tallman, Dan Douer, Steven Gore, et al.
Haematologica|December 3, 2011
Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemiaRoland B Walter, Bruno C Medeiros, Bayard L Powell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemiaArthur E Frankel, Donald R Fleming, Philip D Hall, et al.
Pageof 17

Showing results (11-20 of 164) with videos related to

Sort By:
Pageof 17
Future Oncology (London, England)|September 13, 2019
Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III studyTimothy S Pardee, Sanjeev Luther, Marc Buyse, et al.
British Journal of Haematology|February 19, 2002
Allogenic marrow grafts from unrelated donors with congenital pericentric inversion of chromosome 9Yi-Kong Keung, Mark Pettenati, David D Hurd, et al.
Cancer Genetics and Cytogenetics|July 30, 2003
Constitutional pericentric inversion of chromosome 9 and acute leukemiaYi-Kong Keung, Mary Ann Knovich, Bayard L Powell, et al.
Leukemia Research|May 4, 2004
Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literatureYi-Kong Keung, Michael Beaty, Bayard L Powell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemiaArthur E Frankel, Bayard L Powell, Philip D Hall, et al.
Current Protein & Peptide Science|October 9, 2002
Anthrax fusion protein therapy of cancerArthur E Frankel, Bayard L Powell, Nick S Duesbery, et al.
Journal of Cancer Research and Clinical Oncology|March 6, 2003
19-nor-1alpha,25-dihydroxyvitamin D(2) (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell linesIstván Molnár, Timothy Kute, Mark C Willingham, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 1, 2010
Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapyMartin Tallman, Dan Douer, Steven Gore, et al.
Haematologica|December 3, 2011
Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemiaRoland B Walter, Bruno C Medeiros, Bayard L Powell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemiaArthur E Frankel, Donald R Fleming, Philip D Hall, et al.
Pageof 17